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ABSTRACT 
Clostridium difficile is one of the most important and widespread causes of acute 
gastroenteritis. Due to the limitations of current therapeutic options there is a need for the 
development for new treatment methods. Probiotics are an alternative treatment option that have 
gained prominence in the last few years, and the ability of various probiotics to mitigate            
C. difficile infection was tested. The probiotics Lactobacillus rhamnosus GG and Saccharomyces 
boulardii demonstrated the greatest mitigative effect, showing signification protection against   
C. difficile induced death, bioactive toxin and shedding of pathogen within feces in the germ free 
mouse model. The probiotics also demonstrated protective effects by delaying the onset of        
C. difficile induced mortality as well in the conventional mouse model. Thus, some probiotics 
could potentially be used to help mitigate symptoms of C. difficile associated disease.  
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1 INTRODUCTION  
1.1 Clostridium difficile 
Acute gastroenteritis, characterized by inflammation of the gastrointestinal tract, can lead 
to symptoms such as fever, diarrhea, vomiting, and general malaise. The root cause of 
gastroenteritis can be linked to a variety of sources such as bacteria or viral infections, certain 
toxins, parasites and other factors. The incidence of this disease has been steadily increasing over 
the past few years with around 170 million cases occurring annually in just the U.S. alone (Scallan 
et al., 2011). One of the more notable causes of gastroenteritis which has gained notoriety in the 
last few years is Clostridium difficile (C. difficile).  
C. difficile is a gram positive, spore forming, obligate anaerobic bacterium (Aslam et al., 
2005). While not a normal part of the human microbiota it can still be found in around 3% of 
healthy asymptomatic carriers. This number increases dramatically, however, when looking at 
hospital patients where the number of infected individuals can reach as high as 35% (Aslam et al., 
2005). In fact, C. difficile is one of the main causes of nosocomial diarrhea in the US and in parts 
of Europe (Gorbach et al., 1999). The high infection rate of hospital patients compared to the 
normal population is directly correlated with the use of antibiotics in hospital environments (Hall 
et al., 2012). While it is known that antibiotics are extremely useful in controlling, preventing, and 
curing a wide variety of bacterial infections it is also documented that antibiotics, particularly those 
of the broad-spectrum variety, do not discriminate between the normal commensal microbiota and 
pathogenic bacteria (Lessa et al., 2012). The normal microbiota is one of the key features that helps 
to protect the body from pathogenic organisms through methods such as outcompeting, limiting 
areas where pathogens can establish themselves, and by limiting growth of pathogenic 
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microorganisms (Gareau et al., 2010). These protective effects are especially important within the 
gastrointestinal tract because it faces daily exposer to various foreign microorganisms.   
C. difficile, setting aside the antibiotic resistant strains, is usually not extremely resistant to 
antibiotic treatment. However, C. difficile is able to rebound from antibiotic treatment faster when 
compared to the normal microbiota. This leads to large proliferation of C. difficile and thus massive 
secretion of its two toxins; toxin A, encoded by the tcdA gene, and toxin B, encoded by tcdB gene, 
which work together to cause severe colitis. These toxins act by damaging the intestinal epithelial 
cells as well as acting as attracting leukocytes, primarily neutrophils (Sunenshine et al., 2006). 
This recruitment of neutrophils causes severe diarrhea, abdominal pain, malaises and, in severe 
cases, can lead to characteristic pseudomembranous colitis, toxic megacolon, intestinal 
perforation, and eventually death.  
The treatment for this disease is cessation of antibiotic treatment and, if necessary, 
administration of metronidazole or vancomycin, two antibiotics used to treat C. difficile infection 
(Aslam et al., 2005). This treatment poses a few problems, notably that the antibiotic 
administration was likely important for treatment of a prior illness, while metronidazole and 
vancomycin use is discouraged to prevent the formation of antibiotic resistant strains. This 
antibiotic treatment is also not extremely effective, resulting in relapse rates of around 26% (Aslam 
et al., 2005). Those that relapse also have a higher chance of undergoing further episodes of 
relapse, especially if they take anymore antibiotics (Aslam et al., 2005).  
The diarrhea of those infected with C. difficile contains its spores which can then be spread 
throughout the hospital. These spores can be ingested by other patients leading to their colonization 
and infection. Since these patients are likely to be on antibiotics, when colonized by C. difficile 
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they quickly become infected themselves and become a new source of spore sheading. This cycle 
can lead to outbreaks of C. difficile occurring within the hospital environment.  
One of the most effective treatments for C. difficile is the administration of a Fecal 
Microbiota Transplant (FMT), which consist of taking fecal samples from healthy, C. difficile free 
patients and giving them to infected individuals (Rohlke F et al., 2012). This approach has a high 
success rate, however, some limitations include the fact that administration of FMT has not been 
approved by the FDA and thus to undergo the treatment one must first attempt rounds of traditional 
treatment with metronidazole and vancomycin, as well as other requirements which vary from 
hospital to hospital, must be met to undergo the procedure. Locating and screening healthy C. 
difficile free donors for fecal transplants also adds to the time and cost of this treatment. The idea 
of taking in fecal material from another person can be a concept that some people might find to be 
undesirable. FMTs can also have unintended side effects. For instance, there was a case where a 
patient who underwent FMT with feces from an obese donor became obese themselves (Alang et 
al., 2015).  
Therefore there is a search for low cost, less invasive, and more effective ways in which to 
treat C. difficile associated disease (CDAD). 
1.2 Probiotics 
One option which has gained some prominence in the past few years are probiotics. 
Probiotics are defined as, “Live microorganisms that, when administered in adequate amounts, 
confer a health benefit to the host” (Guarner et al., 1998). These organism have been purported to 
promote healthy gut function in ways such as helping to reduce effects of lactose intolerance, 
reducing constipation, helping ameliorate gut pain caused by Crohn’s disease or Ulcerative colitis, 
and elimination of pathogenic microbes such as H. pylori (Sanders et al., 2013). The means of 
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probiotic action can vary from between the various probiotics but some purported mechanisms 
include acting as a physical barrier, increasing mucosal production, improving tight junctions, 
releasing antimicrobial peptides, and regulation of the immune response (Gareau et al., 2010). 
Probiotics come in a wide variety of various types including both prokaryotic and 
eukaryotic organisms. Various studies have demonstrated that probiotics can have an effect against 
many kinds of pathogens, including some studies on C. difficile. For instance, the probiotic 
Lactobacillus rhamnosus GG (LGG), has been demonstrated to enhance the efficacy of a vaccine 
against rotavirus within the neonatal pig model of infection (Vlasova et al, 2013). LGG has also, 
in conjunction with the probiotic Bifidobacterium breve (BB12), been shown to be effective in 
reducing the duration of diarrhea induced by mild gastroenteritis in a trial using children attending 
day care (Rosenfeldt et al., 2002). LGG, among other lactic acid producing bacteria such as 
Lactococcus lactis, Bifidobacterium lactis, and BB12 have been shown to inhibit the growth of C. 
difficile after coculturing in vitro (Lee et al., 2013).  
The probiotic Saccharomyces boulardii has demonstrated the ability to secrete a protease 
that interferes with the effects of one of C. difficile toxins, toxin A, within the rat ileum 
(Castagliuolo et al., 1996). It has also been shown in various clinical trials to exhibit protective 
effects against C. difficile infection (Tung et al., 2009). 
Gaining a better understanding of which probiotics can be effective against C. difficile in 
vivo and then studying their mechanism of action could lead to better use of probiotics in disease 
treatment. Thus, this study seeks to determine the efficacy and mechanism by which certain 
probiotics can ameliorate C. difficile infection. 
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2     METHODS 
2.1 Animal Experiments 
Mice were housed at Georgia State University’s animal facility. WT C57BL/6 mice were 
obtained from Jackson Laboratories. Mice were transferred to autoclaved cages, food, and water.  
2.1.1 Germ free experiments 
Germ free mice of WT C57BL/6 or Swiss Webster genetic background which were 
raised in GSU germ free facility were transferred into autoclaved changes containing both 
autoclaved food and water. The mice were split into groups and each group was given 200 
ul of 107 CFU/mL via oral gavage of one out of the four different probiotics (Lactobacillus 
rhamnosus GG, Lactobacillus acidophilus, Bifidobacterium breve, or Saccharomyces 
boulardii while the control group received 200 ul of PBS. After 24 hours the mice were 
then challenged with C. difficile (VPI 10463 reference strain ATCC 43255, tcdA +, tcdB+) 
with each mouse receiving 200 ul of 5 x 103 CFU/mL for the C57BL/6 mice or 5 x 104 for 
the Swiss Webster background. 
2.1.2 Conventional Experiments 
C57BL/6 mice were ordered from Jackson Laboratory where upon arrival were 
transferred into autoclaved cages containing both autoclaved food and water. All mice were 
put on an antibiotic cocktail containing the following antibiotics (metronidazole (0.215 
mg/ml), vancomycin (0.045 mg/ml), gentamicin (0.035 mg/ml), colistin (850 U/ml), 
kanamycin (0.4 mg/ml)) within their drinking water for three days. After the 3rd day mice 
were switched to regular autoclaved water. 2 days after switching to regular water mice 
received of clindamycin via intraperitoneal injection. One day post clindamycin injection 
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mice were challenged with C. difficile (VPI 10463) with each mouse receive 200 ul of 1 x 
105 CFU/ml. 
2.2 In vitro Experiments 
2.2.1 qPCR of Clostridium difficile from fecal samples 
PBS+Tween 0.1% was added to fecal samples to obtain a concentration of 
100mg/ml. Samples were shaken using a bead beater for 3 minutes and 250 ul of the fecal 
suspension was removed and 50 ul of SDS 10% was added to each sample. Samples were 
incubated at 64oC for 5 minutes and then 300 ul of Tris-Phenol was added and incubated 
again at 64oC for 5 minutes. 300 mg of glass beads were added and samples were shaken 
through a bead beater apparatus, heated, and centrifuged at 12,000 rpm 5 minutes. 
Supernatant was removed and added to 250 ul of Tris HCL and 400 ul of Tris phenol. 
Samples were vortexed and centrifuged at 12,000 rpm for 5 minutes. Supernatant was 
removed and added to 750ul of chloroform and centrifuged at 12,000 rpm for 5 minutes. 
Supernatant was removed and added to 900 ul of ethanol and incubated at -20 oC overnight. 
Samples were then centrifuged 12,000 rpm for 30 minutes before removal of supernatant. 
300 ul of 75% ethanol was added to pellet and samples centrifuged again for 12,000 rpm 
5. Supernatant was discarded, pellet was dry and finally resuspeneded in 100ul of 
molecular grade water, diluted one 1:5, and stored in -20 until used for qPCR.  
Cell Preparation: Vero cell (ATCC CCL-81) were grown in Dulbecco’s Modified 
Eagle Medium (altered with 10% heat inactivated fetal bovine serum, 1% glutamine, 1% 
Penicillin/Streptomycin) at 37oC at 5% CO2. On day of infection cells were washed with 
PBS and then resuspended in DMEM at a concentration of 1 x 106 CFU/ml. 50 ul of 
suspension was added to 96 well plate.  
7 
Sample Preparation: PBS+Tween 0.1% was added to fecal samples to obtain a 
concentration of 100mg/ml. Samples were shaken for 2 minutes before being centrifuged 
at 12,000 rpm 10 minutes. The supernatant was collected and passed through a 0.22 um 
filter. Samples were then diluted at a 1/10 serial fold dilution in DMEM. 50 ul of samples 
were added to the Vero cells. The cells were incubated for 24 hours at 37oC at 5% CO2. 
Supernatant was then removed and cells were stained with crystal violet. Presence of toxin 
was determined by visual destruction of vero cell monolayer.  
C. difficile spores were cultured in Dr. Shonna McBride’s laboratory at Emory 
University. Spores were kept at room temperature until use, before infection cells were 
heated at 55oC for 20 min in order to eliminate vegetative cells.  
2.2.2 Probiotic Culture 
20 ul of Lactobacillus rhamnosus GG stock, ATCC 53103, was added to 10 mL of 
MRS broth (Difco Lactobacilli MRS Broth 288130) in aerobic conditions overnight at 
37oC. The culture was centrifuged (10 minute 2000 rpm), the supernatant was removed and 
the pellet was resuspended in 10 mL PBS. The culture was then diluted in PBS to desired 
concentration (1 x 107 CFU/mL). 
20 ul of Bifidobacterium breve, Chr-Hansen DSM15954, was added to 10 mL of 
MRS broth (Difco Lactobacilli MRS Broth 288130) in anaerobic conditions, anaerobic 
Oxoid Jar, overnight at 37oC. The culture was vortexed and centrifuged (10 minutes 2000 
rpm). The supernatant was removed and the pellet was resuspended in 10 mL PBS. Culture 
was then diluted in PBS to desired concentration (1 x 107 CFU/mL).  
20 ul of Lactobacillus acidophilus, Chr-Hansen DSM13241, was added to 10 mL 
of MRS broth (Difco Lactobacilli MRS Broth 288130) in aerobic conditions overnight at 
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37oC. Culture was vortexed and centrifuged (10 minutes 2000 rpm). The supernatant was 
removed and pellet resuspended in 10 mL PBS. Culture was then diluted in PBS to desired 
concentration (1 x 107 CFU/mL). 
250 mg of Saccharomyces boulardii, FLORASTOR CAPSULE 7.5 x 107 CFU/mL, 
was dissolved in 5 mL PBS, vortexted and centrifuged (10 minutes at 2000 rpm). The 
supernatant was discarded and the pellet was resuspended in 5 mL PBS. Yeast then diluted 
in PBS to desired concentration (1 x 107 CFU/mL). 
2.2.3 Probiotic Plating 
Probiotic colony forming units (CFU) was determined by growing culture on 
plates. LGG and La5 were grown on Lactobacilli MRS Agar and cultured overnight at 
37oC in aerobic conditions. BB12 was grown on Lactobacilli MRS Agar overnight at 
37oC in anaerobic conditions. S. boulardii was grown on Difco Sabouraud Dextrose Agar 
for 2 days at 30oC. Serial dilutions of probiotics were done in triplicate. O.D. of initial 
culture prior to dilution was taken (O.D. 620) 
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3     RESULTS 
3.1 Fecal Microbiota Transplant and C. difficile 
3.1.1 Clostridium difficile and Fecal Microbiota Transplant 
FMT transplants are well documented as an effective method in treating C. difficile 
infection, however, the efficacy in treating certain strains is unknown. For the experiments 
in this project the C. difficile strain VPI 10463 was chosen because infection causes death 
in susceptible mice beginning two days after infection. This allows for easy determination 
to see if the treatment is or is not effective in mitigating the acute phase of C. difficile 
infection. It is assumed that the microbiota contained within the FMT is the key mechanism 
in providing protection against C. difficile infection. To test this hypothesis, three groups 
of C57BL/6 mice were placed on antibiotics and given two doses of either PBS, frozen 
feces from germ free mice, or frozen feces from healthy C57BL/6 mice (Figure 3.1).  
The results of the experiment show that both of the FMT treatments were able to 
provide some protection against C. difficile infection in a variety of aspects such as reduced 
Figure 3.1 Mouse Germ Free Fecal Microbiota Transplant Experimental Design 
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weight loss, death, and reducing the amount of C. difficile shed in feces. The FMT of both 
conventional and germ free also resulted in lower levels of bioactive toxin (Figure 3.2).  
However, the most impressive result was clearly the FMT delivered from 
conventional feces. This result gives credence to the idea that it is the microbes that provide 
the protection. This experiment also used frozen fecal samples, however, which likely 
reduced the amount of active microbes that were successfully transferred. The experiment 
was repeated, but this time comparing between fresh and frozen feces from conventional 
C57BL/6 mice. This experiment showed a dramatic increase in protection in the fresh fecal 
group (Figure 3.3).  In this experiment the extensive delay in C. difficile induced mortality 
was particularly notable. There were also decreases in the amount of C. difficile and lower 
levels of bioactive toxin of the Fresh group when compared with the PBS and Frozen fecal 
Figure 3.2 Fecal Microbiota Transplant Results: A) Mouse 
survival, B) tcdA transcript Day 1 Post Infection C) Vero cell 
Toxicity Assay Day 1 Post Infection 
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group. These results help strengthen the idea that the main factor in FMT induced 
protection is the microbiota. The focus now turned to see if this protective effect could be 
mimicked using probiotics. 
3.2 Clostridium difficile and Probiotics in Germ Free Mouse Model 
3.2.1.1 Determination of Probiotic efficacy in germ free model 
Four different probiotics were used to test their efficacy in mitigating C. difficile 
infection using a germ free mouse model. Five groups of germ free Swiss Webster mice 
Figure 3.3 Fecal Microbiota Transplant Fresh Samples Results: A) 
Mice Survival B) Body Weight Change C) tcdA Transcript Day 1 Post 
Infection D) Vero Cell Assay Day 1 Post Infection 
Figure 3.4 Germ Free Swiss Webster Mouse Experiment Probiotic Design 
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were each given either PBS, Lactobacillus rhamnosus GG (LGG), Lactobacillus 
acidophilus (La-5), Bifidobacterium breve (BB12), or Saccharomyces boulardii one day 
prior to C. difficile challenge as described in the experimental design (Figure 3.4).   
The probiotics all showed various levels of protection in different areas depending 
on the probiotic used. Of the four, LGG displayed the most effectiveness with 100% of the 
mice surviving C. difficile infection versus the PBS control group. The LGG treated group 
also showed lower levels of C. difficile shed in feces when compared to PBS group. The 
other probiotics showed smaller protective effects versus C. difficile infection with S. 
boulardii being the second most prominent probiotic in terms of protective effect.    
Lactobacillus acidophilus and Bifidobacterium breve showed slight protection by 
delaying the onset of C. difficile induced mortality and severity of mortality respectively 
(Figure 3.5).  
Figure 3.5 Probiotic Results: A) Mice Survival B) Weight Change C) Vero 
Cell Toxicity Assay Day 2 Post Infection D) tcdA Transcript Day 2 Post Infection 
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Based on these results the focus turned to study the ability of LGG and S. boulardii to 
protect against C. difficile associated disease.  
3.2.2 Lactobacillus rhamnosus GG and Clostridium difficile in a Germ Free Mouse 
Model 
Further experiments were undertaken to determine the efficacy of LGG in protecting 
against C. difficile associated disease. The above experiment was repeated, this time 
utilizing C57BL/6 germ free mice in lieu of Swiss Webster. Based on prior observations 
Swiss Webster mice seem to be more resistant to certain pathogenic infections when 
compared to mice of the C57BL/6 background. The experiment was the same save for the 
mouse strain and also that the mice received 1 log lower dose of C. difficile. The LGG 
treated mice again showed 100% survival against C. difficile induced death as well as a 
Figure 3.6 Lactobacillus rhamnosus GG and C. 
difficile GF C57BL/6 Mice A) Mice Survival B) tcdA 
transcript Day 1 Post Infection C) Vero Cell Toxicity Assay 
Day 1 Post Infection D) Vero Cell Toxicity Assay Day 2 Post 
Infection 
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lower amount of C. difficile and bioactive toxin that was shed in the feces. These results 
indicate that LGG is able to provide protection of at least two different strains of mice 
against C. difficile infection in germ free conditions (Figure 3.6). 
3.2.3 S. boulardii and Clostridium difficile in a Germ Free Mouse Model 
The probiotic S. boulardii was also utilized to determine its protective effects of C. 
difficile in a germ free mouse model. S. boulardii was given twice, once 24 hours prior to 
C. difficile infection and once 8 hours prior to C. difficile infection. In these experiments 
the yeast demonstrated its ability to protect against C. difficile Associated Disease. It was 
able to prevent death and showed strong protection against body weight loss. Also, the 
amounts of bioactive toxin in the feces were significantly lower in the yeast treated group 
compared to the control group on day 1 post infection (Figure 3.7). 
Figure 3.7 S. boulardii and C. difficile Germ Free Mice: A) 
Weight Change B)  tcdA transcript Day 1 Post infection C) Vero Cell 
Assay Day 1 Post infection D) Vero Cell Assay Day 2 Post infection 
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3.3 Clostridium difficile and Probiotics in a Conventional Mouse Model 
3.3.1 Clostridium difficile and LGG in a Conventional Mouse Model 
Probiotics showed great efficacy in protecting against C. difficile when given just one 
dose for LGG or two doses for S. boulardii 24 hours prior to C. difficile infection in the 
germ free model of mice. One of the key the limitations within the germ free model, 
however, includes the fact that the probiotics do not have to interact with the normal 
microbiota which could either assist or hinder the probiotics ability to protect against 
infection. To determine the effect that the microbiota has on the ability of probiotics to 
mitigate C. difficile infection, C57BL/6 mice were placed on an antibiotic cocktail for 3 
days before being switched to regular water. One day prior to challenge the mice received 
an intra-peritoneal injection of clindamycin. The mice were given 3 doses of probiotics 
prior to C. difficile challenged (Figure 3.8).  
 
Figure 3.8 Lactobacillus rhamnosus GG + C. difficile 
Conventional Mice Experiment 
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The protective effect of LGG was lower in the conventional experiments when 
compared to the protective effects observed with germ free experiments, however, LGG 
was still able to delay the onset of C. difficile induced death. The probiotic was also able 
to provide a significant reduction in the amount of bioactive toxin as well as increasing the 
weight gain after acute phase of infection had passed (Figure 3.9).  
Figure 3.9 Lactobacillus rhamnosus GG and C. difficile 
Conventional Mice A) Mice Survival B) Weight Change C) tcdA 
Transcript Day 2 PI D) Vero Cell Toxicity Assay Day 2 PI 
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3.3.2 C. difficile and Probiotic Combination in a Conventional Mouse Model 
Based on these results, it was thought that using a combination of probiotics would be 
even more effective in protecting against C. difficile. The two probiotics which showed the 
highest effectiveness against C. difficile, S. boulardii and LGG, were selected. Both 
probiotics were administered at the same time (Figure 3.10). The probiotic combination 
showed slight protection in C. difficile induced death. The majority of the probiotic 
combination protective effect in resisting C. difficile induced death seemed to be 
concentrated within the first 48 to 72 hours post infection. The combination did provide a 
significant reduction in the amount of C. difficile shed in feces as well as lowering the 
amount of bioactive toxin found in the feces when compared to the C. difficile only group 
(Figure 3.11).  
 
Figure 3.10 Probiotic Combination Experimental Design 
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Figure 3.11 Probiotics and C. difficile: A) Mice Survival B) tcdA transcript C) Vero 
Cell Toxicity Assay 
4 CONCLUSIONS 
4.1 Discussion 
 The gut microbiota and its association with the host results in a very complex 
system with numerous different species of microorganisms interacting with each other as well as 
with the host. This delicate balance however, as anyone who has been infected with a food borne 
pathogen such as E. coli can asset to, can be altered by the addition of a single species resulting in 
discord. If the introduction of one or two species of microorganisms can tilt this balance to 
disorder, then the addition of one or two species of other microorganisms might be able to shift 
this balance back to its orderly state.  
This study sought to discover if the use probiotics could be utilized to prevent the effects 
of C. difficile infection. Four different probiotics were used and each demonstrated various effects 
in protecting against C. difficile infection. Both LGG and Bb12 displayed protection against             
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C. difficile induced mortality, while La5 demonstrated the ability to delay the onset of death.            
S. boulardii treatment showed remarkable protection versus weight loss as well as lowering the 
levels of C. difficile 1 day post infection while LGG and BB12 showed lower levels on day 2 post 
infection. These differences in the effects demonstrate a key fact that all probiotics are not equal 
on their effect against C. difficile infection. Some, such as LGG, and S. boulardii, stand out from 
the pack but their effect is not uniform. The difference in their effects leads credence to the idea 
that these probiotics are each working in different ways. 
One must now ask how are the probiotics providing protection? One of the key correlations 
between mice that survive and mice that do not are the lower levels of bioactive toxin. This 
reduction in toxin is also associated with lower levels of C. difficile in the feces. Based on this 
information it is likely that the introduction of probiotics leads to the reduction in the amount of 
C. difficile in the gut. This, in turn, leads to the reduction in the amount of bioactive toxin. This 
reduced toxin amount allows the mice remain more active, letting them consume more food and 
notably water, which prevents them from dying of dehydration.  
How are the probiotics accomplishing the initial reduction in C. difficile? Based on the 
performance of the germ free mouse experiments compared to the conventional ones, the bacterial 
probiotics such as LGG could be acting by outcompeting and limiting the ecological niches that is 
normally available for C. difficile to colonize. It is also possible that LGG and BB12 could be 
releasing antimicrobial factors that can directly target and limit C. difficile growth directly (Lee et 
al., 2013).  
Interestingly, S. boulardii also lowered the amount of C. difficile present in the feces. Of 
the four probiotics tested, S. boulardii showed the lowest amount of colonization potential, 
indicating that the yeast presence in the gut is very transit. This reduces the likelihood that                  
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S. boulardii mechanism of action against C. difficile is operating by outcompeting or taking up 
colonization space. Studies have shown that S. boulardii has a protease that can target C. difficile 
toxins (Castagliuolo et al., 1996). This antitoxin activity could explain the reduction in bioactive 
toxin found in S. boulardii experiments, however, this activity would not account for the reduction 
in the amount of C. difficile shed in the feces. S. boulardii modulation of the host could be a 
possible explanation for this difference. The yeast could be priming the host immune system, 
making it response better to the C. difficile presence. The yeast could also be altering local 
environmental conditions in the gut, such as altering bile acids. 
Some studies have shown that C. difficile show inhibited growth in the presence of 
secondary bile acids (Sorg et al., 2008). Probiotics could potentially modulate these host factors to 
reduce the growth of C. difficile, which would result in lower amounts of toxin. An experiment to 
determine the effect of probiotics on secondary bile acid production could be performed to test this 
theory. Searching for other probiotics which also have the capability of increasing secondary bile 
acids and testing to see if they can demonstrate protective effects against CDAD could also provide 
useful information (Buffie et al., 2014). 
The location of C. difficile infection also seems to be important (Koenigsknecht et al., 
2015). The C. difficile spores start to germinate in the small intestine, and there is even C. difficile 
present in the small intestine during infection, but this does not seem to correlate with disease. 
Rather, C. difficile presence in the large intestine, particularly the cecum, is an important site for 
both sporulation and toxin production. Selecting probiotics which can colonize these areas with 
high efficiency could be one method in which to block C. difficile from establishing itself.    
The fact that the probiotics showed a smaller protective effect within the conventional 
model of C. difficile infection demonstrated some of the limitations in the experimental approach. 
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The mice receiving probiotics in germ free mouse experiments showed significant protection 
versus the conventional experiments. The large difference of effectiveness in the conventional 
mouse model compared with the germ free mouse model most likely lies in two major factors; the 
presence of the antibiotics as well as the presence of the microbiota. LGG was sensitive to the 
presence of gentamycin and clindamycin while displaying resistance to the other antibiotics used 
in the cocktail (Table 1).  
Table 1 Lactobacillus rhamnosus GG Antibiotic Sensitivity 
Kanamycin Resistant 
Gentamicin Sensitive 
Metronidazole Resistant 
Vancoymicin Resistant 
Colistin Resistant 
Clindamycin Sensitive 
 
This sensitivity, particularly towards clindamycin, is important to note. In this model it is 
not known for how long that the antibiotics linger within the mouse after inoculation.  Lingering 
amounts of antibiotics from the cocktail as well as the clindamycin injection could potentially have 
adverse effects on the ability of LGG to maintain a presence within the gut. Also, the 12 hour time 
window between clindamycin administration and the final dose of LGG may not allow for 
clearance of C. difficile from the mouse intestine. The amount of antibiotics lingering within the 
mouse could reduce the probiotics ability to remain active within the mice, leading to a reduced 
action of the probiotic. 
Some ways in which to alter the design and get a better perspective on the probiotic effect 
within the conventional model would be to delay the challenge of C. difficile by one day as well 
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as adding another dose of probiotic. This window should reduce the amount of active antibiotics 
that could be interfering with the probiotic effect. Neutrophil infiltration is also associated with 
CDAD, and measuring serum KC levels could be used to see if probiotic administration is altering 
the inflammatory response to C. difficile, either lowering it to reduce the amount of inflammatory 
damage or increasing it to provide better clearance of the pathogen. The bleeding required would 
likely provide undue stress for the mouse, so another approach would be preferable. Another 
marker that can be used to determine probiotic effectiveness would be to measure Lcn-2 within 
the feces (Chassaing B et al., 2012). This approach would look for general inflammatory response 
rather than neutrophil specific, however, it does provide the advantage of not adding undue stress 
for the mice, allowing one to see if the long term effects of treatment without the risk of mice death 
due to blood collection.  
Based on these experiments probiotics do have the ability to provide some modest 
protection and mitigate some symptoms of C. difficile infection. The question that remains then is 
how effective the probiotic treatment is when compared to the current gold standard of FMTs? The 
probiotics used demonstrated less protection when compared to the FMT treatment. The cause of 
this difference could lie in many areas, but the likeliest resides in the difference in microbial 
content. This result is not too surprising, the FMT contain a complex mixture of a wide variety of 
microorganisms compared to the probiotics used in this study which included only of a single 
strain of probiotic used in each treatment, or two in the case of the probiotic combination approach.  
Is there a role for probiotics in the future of gastroenterology? Yes, the effects of probiotics 
are well documented. Could there be a role for probiotics in the treatment of C. difficile in lieu of 
FMT? Perhaps, to discover this effect the experiments could be repeated with a less virulent strain 
of C. difficile, or restructured to allow more time in-between antibiotic and probiotic 
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administration. Selecting different probiotics, such as those with higher colonization efficiency, 
resistance to certain antibiotics, or those that alter bile acids could result in better protection against 
CDAD, but, with the results demonstrated here FMT still remains the most effective method of 
treating C. difficile associated disease. 
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